Plasma Level Monitoring of DOACs: Balancing Bleeding and Thrombosis Risk
Pall T. Onundarson, Professor Emeritus at Landspitali University Hospital, reposted from Journal of Thrombosis and Haemostasis (JTH) on LinkedIn:
“20 years ago nobody would have been surprised. How else to explain their effect?”
Quoting Journal of Thrombosis and Haemostasis (JTH)’s post on LinkedIn:
“Plasma levels measurement of the 4 direct oral anticoagulants in patients with atrial fibrillation at the time of acute thromboembolic and bleeding events․
This prospective study of 1794 patients with nonvalvular atrial fibrillation found significant interindividual variability in plasma levels of direct oral anticoagulants (DOACs). Low DOAC plasma levels were associated with increased thromboembolic events, while high levels correlated with bleeding events, suggesting plasma level monitoring could help tailor treatment to minimize adverse outcomes.”
Title: Plasma levels measurement of the 4 direct oral anticoagulants in patients with atrial fibrillation at the time of acute thromboembolic and bleeding events
Authors: Cosmo Godino, Riccardo Mazza, Carlo Gaspardone, Alessia Minerva, Rachele Sena, Gianmarco Cozzani, Anna Salerno, Michela Cera, Massimo Slavich, Leila Anna De Lorenzo, Giulio Leo, Giulia Nemola, Annalisa Fattorini, Luciano Crippa, Patrizia Della Valle, Alberto Margonato, Armando D’Angelo

Read the full article here.
Stay updated with Hemostasis Today.
-
Feb 23, 2026, 15:36Simon Senanu: The Peripheral Blood Smear as an Essential Diagnostic Tool in Modern Medicine
-
Feb 23, 2026, 15:32Cheng-Hock Toh: The Paradox of Hematology
-
Feb 23, 2026, 15:20Rabab Al Dawood: Moderating the Coagulation and Hemostasis Session at the ISLH 1st Joint Conference
-
Feb 23, 2026, 15:16Amira Khater: Key Updates on Pulmonary Embolism Management from AHA and ACC Guidelines
-
Feb 23, 2026, 14:45Stacey McGeown: Rare Disease Awareness Day at QUB Marks the Start of Rare Disease Month
-
Feb 23, 2026, 13:53Rare Diseases, Plasma-Derived Medicines and the Elephant in the Room – Part 1
-
Feb 23, 2026, 13:02Deepak Yadav: What 2025 Evidence Tells Us About Stroke Care
-
Feb 23, 2026, 12:55Radoslaw Kaczmarek: Will AAV Gene Therapy for Hemophilia Trigger Tumorigenesis?
-
Feb 23, 2026, 12:46Heghine Khachatryan: More Granular Risk Stratification Framework for PE from The New 2026 AHA/ACC Guideline